Manufacturers of Dupixent Facing Lawsuits Over Drug Outcomes

Multiple Lawsuits Moving Forward After Plaintiffs Claim that Dupixent May Cause Cutaneous T-Cell Lymphoma

MANHATTAN, NEW YORK (June 12, 2026) – Sanofi and Regeneron are facing a variety of lawsuits over claims that Dupixent may cause or potentially accelerate Cutaneous T-Cell Lymphoma.

Plaintiffs were using Dupixent to treat their eczema or other inflammatory conditions. Many of those patients were later diagnosed with Cutaneous T-Cell Lymphoma, which is a rare form of non-Hodgkin lymphoma.

In June of 2026, many of the lawsuits involving Dupixent were brought together by the District of New Jersey. That litigation remains in its early stages at this time.

Despite the lawsuits, the Food and Drug Administration has not yet recalled Dupixent. However, regulators have identified Cutaneous T-Cell Lymphoma as a potential adverse outcome of taking the drug and are weighing whether to take action.

Liability for Injuries Caused by Dupixent

Drug manufacturers have a legal obligation to create products that are reasonably safe. They must study how their products interact with various groups of people and monitor any safety reports related to adverse side effects. When drug manufacturers are aware of a serious risk involving their product, they must warn doctors and patients. With respect to the litigation involving Dupixent, the central question related to liability is whether or not Sanofi and Regeneron failed to warn that their medication could lead to Cutaneous T-Cell Lymphoma. There are a number of other related questions that matter in determining liability.

• It matters whether or not Sanofi and Regeneron knew or should have known about any reports that linked Dupixent to Cutaneous T-Cell Lymphoma.
• It matters whether or not the manufacturers adequately warned doctors about the dangers of the product.
• It matters whether or not patients were kept on Dupixent despite symptoms that may indicate a cancer diagnosis.
• It matters whether or not any delayed diagnosis of Cutaneous T-Cell Lymphoma allowed the disease to progress.

The litigation involving Dupixent is still relatively new. Sanofi and Regeneron will likely dispute that their medication is causally related to Cutaneous T-Cell Lymphoma. The key issue in drug lawsuits is that of foreseeability. If the manufacturers knew or should have known about the risks with their drug and failed to issue adequate warnings, this could form the basis of a liability claim. In many cases, drug manufacturers may not conduct adequate testing of their product to understand the full range of potential side effects.

Steps to Take After Injuries Involving Dupixent

Many people are seriously injured or killed every year due to adverse outcomes from prescription drugs. According to the Centers for Disease Control, “More than 1.5 million people visit emergency departments for ADEs each year in the United States, and almost 500,000 require hospitalization. Older adults (65 years or older) visit emergency departments more than 600,000 times each year, more than twice as often as younger people.” Several steps should be taken after any adverse diagnosis related to Dupixent.

• Victims should preserve all medical records related to their treatment.
• Victims should document their history of taking the medication.
• Victims should continue to seek follow-up medical care.
• Victims should contact an experienced product liability attorney.

It can be difficult to know where to begin after being diagnosed with Cutaneous T-Cell Lymphoma after taking Dupixent. Victims are often left with high medical bills and may need to take extensive periods of time away from work. Sadly, many people never recover. Any person harmed due to the negligent actions of a drug manufacturer should carefully consider their legal options with an experienced attorney. They may be able to seek some measure of accountability or justice through a personal injury claim.

Getting Legal Help for Injuries Caused by Dupixent

We at GLK Law were very concerned to hear about the safety issues associated with Dupixent. The FDA needs to do the right thing and move quickly to protect consumers. Drug manufacturers should be doing everything in their power to ensure that their products are reasonably safe.

Have you or a loved one been diagnosed with Cutaneous T-Cell Lymphoma after taking Dupixent? You may have legal recourse. Our team of experienced personal injury attorneys is here for you. We are committed to helping victims get the medical and financial assistance that they need to move forward with their lives. Whether you just have legal questions or need any type of support, we are here to serve your needs. You can reach out to us anytime at (516) 908-9792.